Hence, relieving the blocks of proliferation and effector function (Fig. 1b), explain the beneficial effect of simultaneous targeting of both PD-1 and LAG-3 by combined nivolumab and relatlimab checkpoint blockade therapy in melanoma. This evidence concerns the gene LAG3 and melanoma.